Key Points
- CEO Martine Rothblatt sold 9,500 UTHR shares on May 4 at an average price of $576.97 for about $5.48M, trimming her stake by 19% to 40,513 shares.
- United Therapeutics topped quarterly EPS ($7.70 vs. $6.78) but missed revenue expectations, and analysts have raised targets—consensus rating is Moderate Buy with an average price target of $601.50.
- UTHR trades near $572 with a market cap of roughly $24.2B, a P/E of about 20.5, a 12‑month high of $607.89, and is heavily institutionally owned (~94%).
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $576.97, for a total value of $5,481,215.00. Following the sale, the chief executive officer owned 40,513 shares of the company's stock, valued at $23,374,785.61. This represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
United Therapeutics Trading Down 1.6%
NASDAQ:UTHR opened at $572.20 on Wednesday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $607.89. The stock has a 50-day moving average price of $545.81 and a 200 day moving average price of $499.25. The stock has a market capitalization of $24.18 billion, a P/E ratio of 20.51, a P/E/G ratio of 1.65 and a beta of 0.60.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to analysts' expectations of $814.80 million. During the same quarter last year, the business posted $6.19 earnings per share. The firm's revenue was up 7.4% on a year-over-year basis. On average, research analysts predict that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the stock. Clearstead Advisors LLC raised its position in shares of United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock worth $117,000 after acquiring an additional 23 shares in the last quarter. Sage Rhino Capital LLC raised its position in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after acquiring an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC increased its position in United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock valued at $276,000 after buying an additional 24 shares in the last quarter. Independent Advisor Alliance increased its position in United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock valued at $406,000 after buying an additional 27 shares in the last quarter. Finally, Bessemer Group Inc. increased its position in United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock valued at $472,000 after buying an additional 28 shares in the last quarter. 94.08% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several analysts recently issued reports on the company. UBS Group increased their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. Bank of America increased their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 31st. Wells Fargo & Company increased their target price on United Therapeutics from $486.00 to $575.00 and gave the stock an "equal weight" rating in a research report on Tuesday, March 31st. Cantor Fitzgerald raised their price target on United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a report on Thursday, March 12th. Finally, Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. Ten analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $601.50.
Get Our Latest Analysis on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
